Thus, DCs but not T cells require SLC38A2 to orchestrate anti-tumour immunity, suggesting that SLC38A2 represents a competitive checkpoint between tumour cells and cDC1s for glutamine acquisition and tumour–immune interactions. The gene discussed is SLC38A2; the disease is neoplasm.